Register now to learn about a new option for relapsed or refractory follicular lymphoma

Risks Versus Benefits in Combining Immunotherapies

Wednesday, February 20, 2019

While combining immune checkpoint inhibitors is often an efficacious way to treat advanced melanoma, it can also cause an increase in adverse events, explained Ryan J. Sullivan, MD, assistant professor of medicine at Harvard Medical School and of hematology/oncology at Massachusetts General Hospital.

For patients with widespread disease who were given a poor prognosis, Sullivan typically prescribes a two-drug regimen, since they need the best chance of response in order to live. However, for most other patients, it is appropriate to give them single-agent immunotherapy treatment, and reassess after 6 to 8 weeks.

Talk about this article with nurses and others in the oncology community in the General Discussions Oncology Nursing News discussion group.
Related Videos
By: Hope S. Rugo, MD, FASCO
By: Kathleen Madden, MSN, RN, APHN, AOCNP, FNP-BC
External Resources

MJH Associates
American Journal of Managed Care
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
OncNurse Resources

Continuing Education
Web Exclusives

About Us
Advisory Board
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright OncNursing 2006-2019
Intellisphere, LLC. All Rights Reserved.